- Home
- GNLX vs MDXH Comparison
GNLX vs MDXH Comparison
Compare GNLX & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- MDXH
- Stock Information
- Founded
- GNLX 2001
- MDXH 2003
- Country
- GNLX United States
- MDXH Belgium
- Employees
- GNLX N/A
- MDXH N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- MDXH
- Sector
- GNLX Health Care
- MDXH
- Exchange
- GNLX Nasdaq
- MDXH Nasdaq
- Market Cap
- GNLX 103.6M
- MDXH 93.1M
- IPO Year
- GNLX 2023
- MDXH 2021
- Fundamental
- Price
- GNLX $2.27
- MDXH $2.26
- Analyst Decision
- GNLX Strong Buy
- MDXH Strong Buy
- Analyst Count
- GNLX 4
- MDXH 2
- Target Price
- GNLX $18.25
- MDXH $7.00
- AVG Volume (30 Days)
- GNLX 142.7K
- MDXH 137.5K
- Earning Date
- GNLX 11-14-2024
- MDXH 11-06-2024
- Dividend Yield
- GNLX N/A
- MDXH N/A
- EPS Growth
- GNLX N/A
- MDXH N/A
- EPS
- GNLX N/A
- MDXH N/A
- Revenue
- GNLX $8,000.00
- MDXH $84,708,000.00
- Revenue This Year
- GNLX N/A
- MDXH $27.57
- Revenue Next Year
- GNLX N/A
- MDXH $20.09
- P/E Ratio
- GNLX N/A
- MDXH N/A
- Revenue Growth
- GNLX N/A
- MDXH 33.01
- 52 Week Low
- GNLX $1.60
- MDXH $1.55
- 52 Week High
- GNLX $16.60
- MDXH $4.64
- Technical
- Relative Strength Index (RSI)
- GNLX 38.68
- MDXH 57.11
- Support Level
- GNLX $2.13
- MDXH $2.12
- Resistance Level
- GNLX $2.80
- MDXH $2.52
- Average True Range (ATR)
- GNLX 0.20
- MDXH 0.16
- MACD
- GNLX -0.04
- MDXH 0.01
- Stochastic Oscillator
- GNLX 14.21
- MDXH 61.19
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.